Your SlideShare is downloading. ×
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
John F. Manzello President
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

John F. Manzello President

324

Published on

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
324
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. John F. Manzello President & CEO [email_address] Promosome LLC, Introduction
  • 2. Management Team John F. Manzello , President and CEO - Established & outstanding track record of 15 years in Director and Executive level management in business/commercial development, fully focused on the introduction of innovative science for bio-production within the biopharmaceutical industry. William J. Gedale, Chairman - Managing General Partner of NGN Capital. 35+ years of Operating Management & Investment experience. Funded a number of activities of The Scripps Research Institute.
  • 3. Scientific Leadership Gerald M. Edelman, M.D., Ph.D., is Chair of Neurobiology at The Scripps Research Institute (TSRI) and, separately, Founder and Director of The Neuroscience Institute. Significant contributions in biophysics, protein chemistry, immunology, cell biology, and neurobiology. Studies on the structure and diversity of antibodies led to the Nobel Prize for Physiology or Medicine in 1972. Vincent P. Mauro, Ph.D., is Associate Professor in the Department of Neurobiology at TSRI. Dr. Mauro and his colleagues have developed selection methodologies to identify IRES elements in mammalian cells and in yeast. He has also demonstrated that powerful synthetic Translational Enhancer Elements (TEEs) can be generated by linking individual IRES elements.
  • 4. Scripps – Our Equity Partner
    • Scripps Partnership:
    • 3 Year Laboratory Funding Agreement in place establishing a relationship with Promosome and the laboratories of Drs. Edelman and Mauro;
    • Promosome has exclusive, sole worldwide rights to license discoveries from the laboratory.
    • Scripps 20+% founder’s interest, subject to normal dilution – no future royalties .
  • 5. Proprietary Technology Advantage
    • Two Key Components:
    • Selection Technology
    • Translational Enhancer Elements (“TEE”s), including IRESes
    • Substantial Enhancements For:
    • Protein production (90% of Promosomes Current Effort)
    • DNA vaccines (10% of Promosomes Current Effort)
    • Future Opportunities:
    • Special reagents
    • Therapeutics
    • Molecular diagnostics
  • 6. Technology Basics
    • Our approach to enhancing protein synthesis involves maximizing translation initiation.
    • Synthetic Translation Enhancement Elements (TEEs)
      • Multiple elements increase number of binding sites
      • More ribosomes are “captured”
      • More protein is created (5-10 Fold Increase of pg/c/d )
    • Development Results Promise Industry Leadership
      • Protein boost of up to 25 fold have been achieved with certain proteins
      • Most recent data has demonstrated 4-5 fold increase (100ml scale) in industry relevant CHO-S lines
      • Works in a variety of mammalian cell lines
      • Works in non-mammalian yeast cell lines
  • 7. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Cell Line Improvements 100’s Promoter Transcription Technologies Cell Culture Process Development 1000’s Translational Enhancement 100’s 10 1
  • 8. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Cell Line Improvements Promoter Transcription Technologies Cell Culture / Process Development Translational Enhancement TIME YIELD
  • 9. The Biotech Industry Challenge Constant Need to Optimize Protein Manufacturing Capacity Repeated Demand for Next Generation of Bioproduction Enabling Technologies Cell Line Improvements Promoter Transcription Technologies Cell Culture / Process Development Translational Enhancement TIME YIELD
  • 10. The Biotech Industry Relief
    • Lower Capital Cost
    • (New SS)
    • Improved Return
    • (Existing SS)
    • Decreased Cost of Goods
    • Increased Margins
    • Greater Speed to Market
    • Competitive Advantage g/l
    • Enablement of Shelved
    • “ Hard to Make” Proteins
  • 11. Market Advantage
    • Our translational approach has been presented to leading Bio-Process Service firms and major Biotech players. The general consensus has been:
    The Most Advanced Molecular Solutions Currently Available Excellent Market Timing Fully Complementary to Previous Industry Advances Purveyors and End Users of Transcriptional Approaches are All Potential Collaborators or Customers Solid IP and Freedom to Practice
  • 12.
    • Promosome expects to achieve revenues of $16 M by Year 3
      • Pretax margins anticipated at 35%
    • Raised $1.9 Million in 2003
      • Institutional investors (17.8%)
      • Private entities (19.8%)
      • Management & board (18.9%)
      • Scientific team (21.2%)
      • Scripps (21.2%) plus consultants (1% as warrants)
    • $7 M in Series B Preferred equity
      • All Series A shareholders plus three new investors have combined to invest $2M Series B “Bridge” in April of 2007. The balance of the B round is anticipated to close Q1 2008.
    Investment
  • 13.
    • Unique model
    • Drives early revenue while positioning company for higher-value therapeutic development
    • World-Class Scientific Team
    • Partnership & Continuing Support from Scripps
    • Exceptional Market Timing
    • Solid Industry Management
    • Grants & Prior Funding, Lower Investment Risk
    • Early Adopters Being Positioned
    Summary

×